JP2011173928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011173928A5 JP2011173928A5 JP2011128592A JP2011128592A JP2011173928A5 JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5 JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- dose
- epothilone
- pharmaceutical formulation
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9803907.6 | 1998-02-25 | ||
| GB9803905.0 | 1998-02-25 | ||
| GBGB9803905.0A GB9803905D0 (en) | 1998-02-25 | 1998-02-25 | Organic compounds |
| GBGB9803907.6A GB9803907D0 (en) | 1998-02-25 | 1998-02-25 | Organic compounds |
| GB9805936.3 | 1998-03-19 | ||
| GBGB9805937.1A GB9805937D0 (en) | 1998-03-19 | 1998-03-19 | Organic compounds |
| GBGB9805936.3A GB9805936D0 (en) | 1998-03-19 | 1998-03-19 | Organic compounds |
| GB9805937.1 | 1998-03-19 | ||
| US09/233,993 | 1999-01-19 | ||
| US09/233,993 US6302838B1 (en) | 1998-02-25 | 1999-01-19 | Cancer treatment with epothilones |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000533117A Division JP2002504511A (ja) | 1998-02-25 | 1999-02-23 | 癌処置のためのエポチロンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011173928A JP2011173928A (ja) | 2011-09-08 |
| JP2011173928A5 true JP2011173928A5 (enExample) | 2012-07-26 |
Family
ID=27451759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011128592A Pending JP2011173928A (ja) | 1998-02-25 | 2011-06-08 | 癌処置のためのエポチロンの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6302838B1 (enExample) |
| JP (1) | JP2011173928A (enExample) |
| AT (1) | ATE483462T1 (enExample) |
| DE (1) | DE69942827D1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386922B1 (en) * | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| US20050042275A1 (en) * | 1999-08-04 | 2005-02-24 | Jean-Claude Sonntag | Epothilone compositions |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| US6893859B2 (en) * | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| IL156988A0 (en) * | 2001-02-20 | 2004-02-08 | Bristol Myers Squibb Co | Pharmaceutical compositions containing epothilone derivatives |
| PL207197B1 (pl) * | 2001-02-27 | 2010-11-30 | Novartis Ag | Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia |
| EP1372650B1 (en) * | 2001-03-19 | 2008-11-19 | Novartis AG | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
| US20070203346A1 (en) * | 2001-04-30 | 2007-08-30 | Oregon State University | Method for synthesizing epothilones and epothilone analogs |
| TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| AU2003235761A1 (en) * | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| CN1649585A (zh) * | 2002-05-01 | 2005-08-03 | 诺瓦提斯公司 | 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物 |
| AU2003296878A1 (en) * | 2002-05-20 | 2004-12-13 | Kosan Biosciences, Inc. | Methods to administer epothilone d |
| RU2379032C9 (ru) * | 2002-06-10 | 2010-03-27 | Новартис Аг | Комбинации, включающие эпотилоны, и их фармацевтическое применение |
| US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| ES2279139T3 (es) * | 2002-10-15 | 2007-08-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo. |
| CA2526285A1 (en) * | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| EP1641449A1 (en) * | 2003-06-27 | 2006-04-05 | Novartis AG | Cancer treatment with epothilones |
| CN1870995A (zh) * | 2003-09-02 | 2006-11-29 | 诺瓦提斯公司 | 使用埃坡霉素的癌症治疗 |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| WO2006010082A1 (en) * | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| CA2584368A1 (en) * | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| WO2006055742A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| PL2450437T3 (pl) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc | Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| CA2744713A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | Raf inhibitors and their uses |
| MX2011010045A (es) * | 2009-03-25 | 2011-10-11 | Novartis Ag | Composicion farmaceutica que contiene un farmaco y siarn. |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| CA2927832C (en) | 2010-05-18 | 2021-03-23 | Cerulean Pharma Inc. | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| DE59609305D1 (de) | 1995-11-17 | 2002-07-11 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Herstellung |
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| ES2290993T3 (es) | 1997-08-09 | 2008-02-16 | Bayer Schering Pharma Aktiengesellschaft | Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica. |
-
1999
- 1999-01-19 US US09/233,993 patent/US6302838B1/en not_active Expired - Lifetime
- 1999-02-23 AT AT99910257T patent/ATE483462T1/de active
- 1999-02-23 DE DE69942827T patent/DE69942827D1/de not_active Expired - Lifetime
-
2011
- 2011-06-08 JP JP2011128592A patent/JP2011173928A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856646C (en) | Combination treatment of cancer | |
| JP2014515373A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2023541432A5 (enExample) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2015512406A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| JP2020514412A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| NZ711179A (en) | Oral formulations of deferasirox | |
| JP2012193216A5 (enExample) | ||
| JP2010521417A5 (enExample) | ||
| JP2010526101A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP2016516773A5 (enExample) | ||
| JP2018531605A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2016505050A5 (enExample) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2019507786A5 (enExample) | ||
| JP2020510043A5 (enExample) | ||
| JP2024531799A5 (enExample) |